Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study

Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's disease (CD) in a real-world setting (clinicaltri...

Full description

Bibliographic Details
Main Authors: Maria Fleseriu, Chioma Iweha, Luiz Salgado, Tania Longo Mazzuco, Federico Campigotto, Ricardo Maamari, Padiporn Limumpornpetch
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Endocrinology
Subjects:
Cushing's disease
pasireotide sc
somatostatin analog
clinical practice
real world
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2019.00436/full

Internet

https://www.frontiersin.org/article/10.3389/fendo.2019.00436/full

Similar Items